Research analysts who have asked questions during MESOBLAST earnings calls.
LC
Louise Chen
Cantor Fitzgerald
5 questions for MESO
Also covers: AMGN, ARDX, CNTB +16 more
ET
Edward Tenthoff
Piper Sandler Companies
3 questions for MESO
Also covers: ARVN, ARWR, CAPR +14 more
John Hester
Bell Potter Securities
2 questions for MESO
Also covers: RCEL, TLX
SC
Sami Corwin
William Blair
2 questions for MESO
Also covers: ALLO, BEAM, KRYS +5 more
ES
Elyse Shapiro
Canaccord Genuity Group
1 question for MESO
Michael Okunewitch
Maxim Group
1 question for MESO
Also covers: BLFS, BLTE, BNGO +11 more
OB
Olivia Brayer
Cantor
1 question for MESO
Also covers: AMGN, AUPH, BMRN +8 more
Recent press releases and 8-K filings for MESO.
Mesoblast Reports Strong Ryoncil Sales and Secures New Financing in Q2 2026
MESO
Earnings
Debt Issuance
New Projects/Investments
- Mesoblast Limited reported Ryoncil® net revenues of US$30 million for the quarter ended December 31, 2025, with gross sales increasing 60% to US$35 million compared to the prior quarter.
- The company secured a new US$125 million non-dilutive credit-line at a fixed interest rate of 8.00% per annum, with US$75 million initially drawn, and held US$130 million in cash at December 31, 2025.
- Net operating cash spend for the quarter was US$16 million, and the company estimates 11.6 quarters of funding available based on current cash and unused facilities.
- Mesoblast received positive FDA feedback on a potential Biologics License Application (BLA) filing for rexlemestrocel-L in chronic discogenic low back pain and expects to commence a pivotal trial for Ryoncil® in adults with severe SR-aGvHD this quarter.
Jan 29, 2026, 1:17 PM
Mesoblast Reports Strong Real-World Survival Data for Ryoncil® in Pediatric SR-aGvHD
MESO
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Mesoblast Limited reported 84% survival (21 out of 25 patients) in children with steroid-refractory acute graft-versus-host disease (SR-aGvHD) after completing the initial 28-day treatment regimen with Ryoncil® (remestemcel-L-rknd) since its commercial availability in March 2025.
- Ryoncil® is available through 45 onboarded transplant centers and is covered by government and commercial payers for over 260 million U.S. lives.
- The issuance of a specific HCPCS J-Code on October 1, 2025, for billing and reimbursement resulted in greater usage of Ryoncil® under CMS coverage in the last quarter.
- The company plans to expand the FDA label for Ryoncil® to adults with severe SR-aGvHD, a market approximately three times larger than the pediatric population, with a pivotal trial expected to commence site enrollment this quarter (Q2 2026).
Jan 28, 2026, 8:26 PM
Mesoblast Receives Positive FDA Feedback on Rexlemestrocel-L for Chronic Low Back Pain
MESO
Product Launch
New Projects/Investments
- The FDA acknowledged that the effects on pain intensity favor Mesoblast's rexlemestrocel-L and confirmed that a clinically meaningful reduction in pain intensity at 12 months can support product efficacy for chronic discogenic low back pain (CLBP).
- The FDA also stated that robust results on opioid reduction from an adequate and well-controlled trial could be included in the Clinical Studies section of the product labeling for rexlemestrocel-L.
- Mesoblast's second randomized controlled Phase 3 trial (MSB-DR004) for rexlemestrocel-L is over 50% enrolled and is expected to complete its 300-patient enrollment target within the next three months.
Jan 20, 2026, 10:42 PM
Mesoblast Reports Strong Ryoncil Sales Growth and New Financing Facility
MESO
Earnings
Revenue Acceleration/Inflection
Debt Issuance
- Mesoblast Limited announced gross revenue of US$35.1 million from Ryoncil® sales for the quarter ended December 31, 2025.
- This represents a 60% increase in Ryoncil® sales compared to the prior quarter ended September 30, 2025.
- The company secured a new US$125 million five-year interest-only facility, which allowed for the full repayment of its prior senior secured loan and partial repayment of its subordinated royalty facility.
- The new financing facility offers a substantially lower overall cost and provides greater flexibility for strategic partnerships and commercialization.
- Ryoncil®, the first FDA-approved mesenchymal stromal cell product, will be evaluated in a pivotal trial for adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), a market approximately three times larger than the pediatric market.
Jan 9, 2026, 12:59 AM
Mesoblast refinances debt with new credit facility
MESO
Debt Issuance
- Mesoblast Limited repaid its existing senior secured loan and partially repaid its subordinated royalty facility by drawing US$75 million from a new five-year credit facility.
- The new facility, provided by an existing shareholder and director, features a fixed interest rate of 8.00% per annum, a substantial reduction from previous debt facilities, and includes a five-year interest-only period.
- An additional US$50 million can be drawn by Mesoblast until June 30, 2026, and the facility does not encumber any material assets or intellectual property, providing greater financial flexibility.
- In connection with the facility, the provider will receive 5-year warrants to purchase approximately 323,000 American Depositary Shares (ADSs) at US$21.51 per ADS, subject to shareholder approval by November 30, 2026.
Dec 30, 2025, 12:10 AM
Mesoblast Issues Warrants as Commitment Fee for Convertible Note Facility
MESO
Debt Issuance
- Mesoblast Limited issued 5,000,000 unquoted WARRANTS 3 on December 17, 2025.
- These warrants were issued as a commitment fee for an up to US$50 million convertible note facility.
- The warrants have an exercise price of AUD 2.50 and an expiry date of December 17, 2029.
- 3 million of these warrants will only vest and become exercisable if the company exercises its option under the convertible note facility.
Dec 18, 2025, 2:58 AM
Mesoblast's Remestemcel-L Shows Superior Outcomes in SR-aGvHD Treatment Study
MESO
New Projects/Investments
- An independent meta-analysis presented at the 67th ASH Annual Meeting concluded that Mesoblast's remestemcel-L demonstrated superior outcomes in complete and overall remission compared to ruxolitinib for treating steroid-refractory acute graft versus host disease (SR-aGvHD).
- The study involved 2,732 patients, with 644 receiving remestemcel-L and 1,349 receiving ruxolitinib across 11 studies.
- Mesoblast's Ryoncil® (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell (MSC) product and the only one approved for children under age 12 with SR-aGvHD.
- The company holds a strong global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection through to at least 2044.
Dec 12, 2025, 1:09 AM
Mesoblast Reports Strong Ryoncil Launch and Outlines Pipeline Progress
MESO
Product Launch
Guidance Update
New Projects/Investments
- Mesoblast's Ryoncil for pediatric acute acute graft-versus-host disease (aGVHD) achieved $30 million in net sales in the first two quarters of 2025, with current quarter (Q4 2025) sales projected to be greater than $30 million.
- The company plans to expand Ryoncil into the adult aGVHD market, which is three times larger than the pediatric market, with a potential 2027 filing for label extension following a planned 12-month enrollment for a randomized controlled trial.
- Mesoblast anticipates filing a Biologics License Application (BLA) for Revascor in heart failure patients with a left ventricular assist device (LVAD) in the first quarter of 2026.
- A second trial for Revascor in chronic lower back pain is ongoing, with enrollment expected to complete in the first quarter of 2026 and a 12-month readout, showing potential for opioid avoidance.
- The company reported approximately $146 million in cash at the end of Q3 2025 and anticipates potentially reaching break-even by mid-2026.
Dec 4, 2025, 5:00 PM
Mesoblast Provides Updates on Ryoncil Launch, Revascor Filings, and Financial Outlook
MESO
Product Launch
Guidance Update
New Projects/Investments
- Mesoblast reported net sales of $30 million for Ryoncil in the first two quarters and expects over $30 million in the current quarter, indicating a strong launch in pediatric acute graft-versus-host disease (aGVHD).
- For Ryoncil's adult aGVHD indication, a randomized controlled trial is planned, with enrollment expected to take 12 months and a 2027 filing targeted for potential label extension.
- The company anticipates filing a Biologics License Application (BLA) for Revascor in heart failure patients with a left ventricular assist device (LVAD) in Q1 2026.
- Enrollment for a confirmatory Phase III trial of rexlemestrocel-L (Revascor) for chronic lower back pain is projected to complete in Q1 2026, with a 12-month readout.
- Mesoblast reported approximately $146 million in cash at the end of the last quarter and aims to potentially reach break-even by mid-2026.
Dec 4, 2025, 5:00 PM
Mesoblast Provides Update on Product Launches, Pipeline, and Financials
MESO
Product Launch
Guidance Update
New Projects/Investments
- Mesoblast's Ryoncil for pediatric acute aGVHD has achieved $30 million in net sales over the first two quarters, with the current quarter (Q4 2025) projected to exceed $30 million.
- The company plans to file a Biologics License Application (BLA) for Revascor in heart failure patients with a left ventricular assist device (VAD) in the first quarter of 2026.
- A randomized controlled trial for Ryoncil in adult steroid-refractory acute graft-versus-host disease is commencing, targeting a 2027 filing for label expansion.
- Mesoblast reported approximately $146 million in cash at the end of Q3 2025 and anticipates potentially reaching break-even by mid-2026.
Dec 4, 2025, 5:00 PM
Quarterly earnings call transcripts for MESOBLAST.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more